Track record · closed signal

Elanco Animal Health Inc. (ELAN) — closed signal from July 17, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on October 15, 2025.

Predicted vs. what happened

ELAN price · publication thesis → realized outcomesplit-adjusted
$14.87 Published $18.59 Target $20.51 Window close $21.76 Peak
$14.60 – $15.00Entry zone — fair-value band
$14.87Published — price the day we called it
$18.59Target — the price the thesis aimed for
$21.76Peak — highest point inside the window, not a realized return
$20.51Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 41 days.

Peak price
$21.76
peak on October 7, 2025 — not a realized return
Peak gain
+46.3%
peak, from the publication price
Window close
$20.51
end-of-window price, context only
Days to target
41
Window
July 17, 2025 – October 15, 2025

The thesis — published July 17, 2025

Predicted growth
+25%
over the measurement window
Target price
$18.59
the price the thesis aimed for
Entry zone
$14.60 – $15.00
the fair-value band we waited for
Price at publication
$14.87
published July 17, 2025
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Investment bank Leerink now rates Elanco as a top pick. Option prices imply traders expect a sharp swing when results arrive on 7-Aug. After months of falling, the share price looks beaten down and could climb to 19-20 dollars within three months if sales and profits beat expectations. A 400 million-dollar cost-cut program and several new animal medicines give extra fuel. With fewer sellers left, any good news could spark a quick jump.

Primary drivers

  • Leerink's new top pick rating boosts market mood and draws fresh interest.
  • Extremely low reading hints the sell-off may be done, allowing tight exit plans.
  • Costly options suggest traders expect a big price swing at earnings time.
  • Saving 400 million dollars should widen profits as fresh products reach customers.

How it played out

ELAN: target reached in 41 days

Lyra published ELAN at $14.87 on 2025-07-17 with a short-term setup that expected 25% growth. The thesis pointed to Leerink's top pick rating, a beaten-down share price, costly options around 7-Aug results, a 400 million-dollar cost-cut program, and fresh animal medicines as possible fuel for a move toward the target.

Inside the window, ELAN reached a peak of $21.76 on 2025-10-07, a 46.3% gain. The target price of $18.59 was reached in 41 days. The stock ended the window at $20.51. The thesis played out, and the move went beyond the published target.

What happened during the window

On Aug. 8, 2025, Investor's Business Daily reported that ELAN's Relative Strength Rating rose from 77 to 89. The same article said sales growth improved from -1% to 5%.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.